

Respiratory tract infections in children: epidemiology, management, prevention, and total impact on the society

Research group: Terho Heikkinen, MD, PhD, Assistant Professor of Pediatrics, Department of Pediatrics, University of Turku, Kiinamyllynkatu 4-8, 20520 Turku.

Email: terho.heikkinen@utu.fi, Phone: +358-2-3132434, +358-50-5359095. **Senior researchers:** Santtu Heinonen, MD, PhD; Heli Silvennoinen, MD, PhD; Janne Kataja, MD, PhD; Tuomo Puhakka, MD, PhD. **Doctoral candidates:** Heikki Valkonen, MD.

Project description: This clinical research project focuses on timely and clinically important questions in the field of respiratory infections and their complications in children. The goal of the project is to produce reliable and useful information that would be directly applicable to everyday clinical practice and that could also guide health care-related political decision-making.

Publications:

- Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Vahlberg T, Ziegler T, Ikonen N, Puhakka T, Heikkinen T. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. **Clin Infect Dis** 2010;51:887-94.
- Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. **Pediatr Infect Dis J** 2011;30:e24-e28.
- Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. **Lancet Infect Dis** 2011;11:23-9.
- Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. **Clin Infect Dis** 2014;59:1519-24.
- Silvennoinen H, Huusko T, Vuorinen T, Heikkinen T. Comparative burden of influenza A/H1N1, A/H3N2 and B infections in children treated as outpatients. **Pediatr Infect Dis J** 2015;34:1081-5.

Number of Ph.D theses in 2010-2015: 2

External funding in 2015: GlaxoSmithKline, Novavax.